Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Re: Nano drug delivery

June 27, 2016 | A version of this story appeared in Volume 94, Issue 26

[+]Enlarge
Credit: Gaël McGill/Digizyme
A box showing median delivery efficiencies, diameters, and targeting methods.
Credit: Gaël McGill/Digizyme

“Does Nanomedicine Have a Delivery Problem?” (C&EN, June 20, page 16), which surveyed the state of cancer nanomedicines’ delivery efficiencies, piqued readers’ interest.
cenm.ag/nanodelivery

Short answer [to the story’s headline]: YES! This is the holy grail pursuit of our time.

Carolyn Bertozzi ­­(@­CarolynBertozzi) via Twitter

Great article. Critical reviews that highlight shortcomings and challenges in a field instead of only the advances are the most educational in my opinion.

David McLeod via Facebook

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.